BUY
Initiation Report November 5, 2021
Alzamend Neuro
NASDAQ: ALZN: $2.29 Target: $15.00
James Jang
Director of Research
jjang@univest.us
212.343.8888
From the Earth to the Brain, Lithium Puts the
Li in Life: Initiating Coverage of Alzamend
(ALZN)
Investment recommendation
Investment Highlights
• AL001 use for Alzheimer’s Disease is a way to shorten the timeline for
the other indications of depression, PTSD, and bipolar disorder where
we believe there is a better market for lithium. The FDA has programs
in place for breakthrough therapies and fast track that allow
experimental drugs to get through the approval process faster.
Alzamend has the potential to file for these programs with their AL001
drug for Alzheimer’s, which would allow for quicker data gathering that
can then be used for the other indications. Since AL001 will be the
same formulation for each indication, safety and tolerability can be
skipped for the other indications and trials can smaller and quicker
which can reduce time to approval.
• Reformulation of an approved therapy allows for easy acceptance with
safer profile. Lithium Carbonate has been an approved therapy for
many years for bipolar disorder and off-label use for depression. While
it is an approved therapy, there are still many risks associated with this
treatment; with high levels of lithium causing liver and kidney damage.
Alzamend’s new formulation helps to limit these issues while extending
the therapeutic window (reduce dosage), while maintaining a high level
of efficacy. Since Lithium is an approved therapy, we expect AL001 to
have a shorter pathway through clinical trails. This should lead to a
reduction in the time to approval, lower costs, and the potential for
quicker revenue generation.
Based on our discounted cash flow (DCF) methodology, we value ALZN at
$15 per share which is based on about a 1.0x multiple to our DCF derived
price of $14.81. Currently, we are conservatively omitting AL001 and AL002
indications for Alzheimer’s Disease from our estimates at this time. While we
believe ALZN’s differentiated approach to Alzheimer’s Disease could serve as
a major catalyst, at this time we view the AL001 and AL002 programs for
Alzheimer’s Disease as a free call option at current valuation levels. Therefore,
we initiate coverage of ALZN with a BUY rating and $15 price target.
REVENUE (000s)
EBITDA (000s)
Consumer Products - Nutraceuticals
EPS
We are initiating coverage of Alzamend Neuro (ALZN) with a BUY rating and
$15 price target. We believe ALZN could unlock a quicker pathway to
revenue generation by utilizing its patented AL001 (LiProSal) ionic cocrystal
to treat a host of psychiatric disorders.
The recommendations and opinions expressed in this research report accurately reflect the Investment Analyst’s personal, independent, and
objective views about any and all the Designated Investments and Relevant Issuers discussed herein. For important information, please see
the Import Disclosures section in the appendix of this document.
SHARE PRICE PERFORMANCE
Valuation
Cash (000)
GAAP EPS
BIOTECHNOLOGY F2021 F2022E F2023E
1Q ($0.03)A ($0.03)E
2Q ($0.02)E ($0.03)E
3Q ($0.02)E ($0.03)E
4Q ($0.02)E ($0.02)E
FY ($0.07)A ($0.10)E ($0.10)EF2021 F2022E F2023E
1Q $15,618A $8,461E
2Q $14,880E $4,938E
3Q $13,533E $13,393E
4Q $12,032E $11,614E
FY $1,929A $12,032E $11,614E -
10,000,000
20,000,000
30,000,000
40,000,000
50,000,000
60,000,000
$2.00
$4.00
$6.00
$8.00
$10.00
$12.00
$14.00
6/15/2021 7/15/2021 8/15/2021 9/15/2021 10/15/2021
Volume (RHS) Price (LHS)Comp a ny St a t ist ics
Closing Price 11/4/2021 $2.29
52-week Range $2.04 - $33.55
Market Cap (M): $198.97
Avg. Daily Volume: 2,119,516
Debt (M): 0.34
Risk Profile: High
Fiscal Year End: April
Recent ALZN News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/11/2024 08:30:19 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/03/2024 08:30:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/31/2024 08:59:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:30:23 PM
- Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel • Business Wire • 05/22/2024 12:00:00 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:30:15 PM
- Alzamend Neuro Announces Initial Closing of Private Placement • Business Wire • 05/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:30:25 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/10/2024 09:06:26 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/10/2024 08:30:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 10:30:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:20:24 PM
- Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million • Business Wire • 05/09/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/07/2024 08:31:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:33 PM
- Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program • Business Wire • 05/07/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:30:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:30:30 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients • Business Wire • 12/11/2023 01:00:00 PM
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients • Business Wire • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:30:19 PM
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement • Business Wire • 11/16/2023 01:00:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM